The latest Investing Matters Podcast episode with Inclusive Asset Management's Alexandra McGuigan has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Prof Popat says the use of blood tests or 'liquid biopsies' is likely to broaden to breast cancer and cancers in children.
https://www.bbc.co.uk/news/health-68624334
The tablet in the article is provided by Takeda which has a $45B MCAP
EVGEN PHARMA PLC - Investor Presentation
53 views 1 day ago
https://youtu.be/_H0xBzEyJMw?si=8mee0VASv1I4gBUQ
Cash runway to 2026 is what they said during the investor presentation.
Dsflat - I was a little confused with your comment, the cash runway was previously end of 2024, how have you now got to 2026. Please correct me if I'm wrong but aren't they spending all the funds raised on the acquisition.
chronoscreen™ presentation was either swerved because it could be a threat to stalicla and firefly diagnostics and 'the deal'
or chronoscreen™ is a bag of ****e not worthy of mention ....
After the investor presentation I gave feedback that there could have been some mention of Chronoscreen™
"Chronos dedicated laboratory in Oxford which screens for activity of drugs in brain disease through its proprietary platform, Chronoscreen™ "
Bring up Chronoscreen™ and talk about how it works and maybe sprinkle with some planned AI integration and it might raise investor interest...
Just my thunking
Cash runway to 2026 is what the BOD stated today.
Perhaps this deal will persuade Stalicla to proceed in case Evgen find a better offer for SFX-]1.
Depending on whether the placing shares go into sticky hands we could see some steadying and uptrend if approved is gained at the AGM.
Exciting developments here in a niche market for unmet needs for neurological disorders and disease but it is seems long journey to commercialisation unless there is Big Pharma involvement to expedite urgent treatment for long suffering patients
Thanks, Trickymatters, but have not dumped the rump holding yet.
New tax year, unless some magic happens before then, lol.
We have seen some token inside buying, but really nowhere near enough IMO to make participation an attractive proposition. GLA.
FYI the Firefly merger with Wavedancer was approved by shareholders on the 18th which will give them a Nasdaq listing.
https://wavedancer.com/
For those wondering why I'm mentioning this, Stalicla announced that they were working with Firefly a year ago;
https://stalicla.com/media/news/firefly-neuroscience
I think this acquisition has been on the cards for a while.
Maybe since HUW resigned his directorship.
It could also explain HUW's claim that he was unable to purchase shares.
Maybe they were hoping to have the stalicla money by now and have had to restructure the deal.
Dont think this undermines any deal with stalicla because that relates to sfx01 only and is associated quite specifically with neurodevelopmental disorders.
I hate the new name and often associate name changes with desperation.
Is that you, Huw? Lol.
CEO, Dr Huw Jones, and CFO, Toni Hänninen and CBO, Dr Helen Kuhlman, will provide a live presentation on the acquisition of Chronos Therapeutics, the Placing and Subscription, the Retail Offer and the change of name as detailed in this Announcement and the Circular.
The presentation will take place via the Investor Meet platform on Wednesday 20 March at 10am GMT.
https://otp.tools.investis.com/clients/uk/evgen_pharma1/rns/regulatory-story.aspx?cid=1240&newsid=1800940
BOOM
Great news ;-)
You should all look on this as a positive, it could have been so much more and really diluted existing shareholders plus they can now say they have a 1 year runway. Let's just hope the bods finally contribute, it would be truly shocking if they again remained on the sidelines.
CJ.
2024 is the year of avoiding almost all Pharma/Bio's, it's quite clear you cannot trust or believe any of the numbers or cash they claim to have or the runway they claim it will last to. I had quite a few Rene when that was suspended and I thought I had a good 3-6 month safety net to get them out when they were suddenly suspended with no money and this is probably the tip of the iceberg. Avct got a lot of stick for their 50p placing but infact it was a stroke of genius raising all that money while they had the chance, most stocks prices are tanking with little hope of getting a sensible price for their next funding, infact most need a miracle.
To be honest, I am pondering whether to notify the authorities to see whether they think this looks 'off' too, but I am not sure that I have much faith in them either.
Glad it was not just me that came to a...less than positive opinion on this latest update.
Take it you will not be participating in this raise then? Lol.
If I put my Rose Tinted Glasses on again I could imagine that Evgen have seen the results with Stalicla and have surmised that Stalicla are trying to hold SFX-01 down on the back of good results...
The deal could show that EVG will go it alone if necessary using the Chronos dedicated laboratory in Oxford which screens for activity of drugs in brain disease through its proprietary platform, Chronoscreen™
I don't know how else to read what has happened today ??
Can anyone make sense of this? Evgen maintained that they have enough money to last to the end of 2024 and are expecting up to $5.5m by the end of the year from Stalicla. So why issue a share placing now to raise a pathetic £1m which will only fund the company an extra four months and dilute the shares considerably.
I always feared this would happen.
This doesn’t bode well at all for the Stalicla deal if Evgen are raising funds from a placing now.
Start with Companies House and the list of Directors in that outfit.
Certainly would be interested in the opinions of others here on this latest development.
Quite a bit to digest there
Staclica lawyers would have requested phase 2 info removed from their website whilst the payment is under investigation.
My interpretation is that there is a new BoD at Staclica and everything is under review.
Radar,
The facts are facts..
An update on the dispute will be issued when Both parties Come to a conclusion.
WE don't know if the conclusion will be favorable or not for us , Evg shareholders ..
Meanwhile the market has priced in the risk .
Biotech investing demands patience and risk management so everyone to their own trades and convictions !
You can hope all you want until the cows come home or there are elephants in the sky.
Hope will not change the facts, son.